Amgen Inc Stock Price, News & Analysis

Amgen will present at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference on Sept. 16, 2020, at 11:45 a.m. ET. CEO Robert A. Bradway will lead the presentation, which can be accessed live via Amgen's website. A replay will be available for 90 days post-event. Amgen focuses on innovative therapeutics for serious illnesses, leveraging advanced human genetics to improve health outcomes. With a history dating back to 1980, Amgen is a leader in biotechnology.

Amgen will present at Citi's 15th Annual Virtual BioPharma Conference on September 10, 2020, at 2:25 p.m. ET. Key executives, Murdo Gordon and Peter H. Griffith, will deliver the presentation. Interested parties can access live audio via Amgen's website, with a replay available for 90 days post-event. Founded in 1980, Amgen is a leading biotechnology company focused on innovative therapeutics, emphasizing solutions for serious illnesses and unmet medical needs. For more details, visit www.amgen.com.

Amgen announced positive results from the HAUSER-RCT Phase 3b study for Repatha® (evolocumab) in pediatric patients aged 10-17 with heterozygous familial hypercholesterolemia (HeFH). The study demonstrated a significant 38.3% reduction in LDL-C levels compared to placebo, meeting its primary endpoint. It was presented at ESC 2020 and published in The New England Journal of Medicine. No new safety risks were noted, with adverse events being generally mild. The study emphasizes Repatha's potential as a safe and effective option for managing high cholesterol in children.

Amgen has announced the presentation of 12 scientific abstracts at ESC Congress 2020, showcasing research on Repatha® (evolocumab). This includes the first Phase 3 study involving pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and studies on lipid-lowering therapy across Europe. Key findings highlight Repatha’s role in managing LDL cholesterol in high-risk patients, addressing unmet medical needs in cardiology. The congress will take place from Aug. 29 to Sept. 1, 2020, with various presentations scheduled.

Amgen's KYPROLIS® (carfilzomib) has received FDA approval for expanded use in combination with DARZALEX® (daratumumab) and dexamethasone (DKd) for treating relapsed or refractory multiple myeloma (R/R MM). This regimen can be administered once or twice weekly and is aimed at patients who have undergone one to three lines of therapy. The Phase 3 CANDOR trial demonstrated a 37% reduction in disease progression risk for DKd compared to Kd alone. The approval meets the growing need for effective treatments following the use of immunomodulatory drugs.

Amgen (NASDAQ:AMGN) has announced new terms for its Exchange Offers, now increasing the maximum principal amount of New Senior Notes to $940 million. The Exchange Offers involve a variety of its Senior Notes, exchanging them for a mix of cash and new notes due 2053. The offers include notable yields such as 2.370% for 6.90% Senior Notes due 2038. The early settlement date for validly tendered notes is set for August 17, 2020. The Exchange Offers are aimed at qualified institutional buyers and select non-U.S. investors only.

Amgen announced early results for its private Exchange Offers to exchange certain series of its senior notes for new Senior Notes due 2053. The total principal amount of New Notes issued will not exceed $800 million, and the New Notes Premium is capped at $350 million. The Exchange Offers include ten series of Old Notes, with a total outstanding principal of approximately $2.19 billion. Validly tendered Old Notes as of August 12, 2020, are prioritized for exchange, with completion expected by August 28, 2020. The Offers are limited to certified institutional holders.

Amgen announced on July 30, 2020, the launch of nine private exchange offers for its outstanding senior notes, totaling up to $800 million in New Notes due 2053. The offers include various senior notes due between 2037 and 2045, with specific cash payment percentages based on acceptance priority levels. The exchange is contingent on meeting certain conditions, including a minimum issuance of $300 million in New Notes and adherence to yield conditions. The offers will expire on August 26, 2020, unless extended. Eligible holders can receive early exchange premiums if they participate by August 12, 2020.

Amgen reported Q2 2020 revenues of $6.2 billion, a 6% increase year-over-year, attributed to 13% volume growth in newer products like Otezla and Repatha. GAAP EPS fell 15% to $3.05, mainly due to amortization from the Otezla acquisition. Non-GAAP EPS rose 7% to $4.25. The company generated $2.7 billion in free cash flow and maintained its 2020 revenues guidance at $25.0-$25.6 billion. Despite COVID-19 impacts on product demand, Amgen continues to navigate the pandemic effectively, with pipeline updates expected soon.